| Item Type | Name |
|
Concept
|
Maximum Tolerated Dose
|
|
Academic Article
|
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
|
|
Academic Article
|
MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
|
|
Academic Article
|
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
|
|
Academic Article
|
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
|
|
Academic Article
|
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
|
|
Academic Article
|
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
|
|
Academic Article
|
Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
|
|
Academic Article
|
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
|
|
Academic Article
|
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
|
|
Academic Article
|
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
|
|
Academic Article
|
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
|
|
Academic Article
|
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
|
|
Academic Article
|
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.
|
|
Academic Article
|
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
|
|
Academic Article
|
A phase 1 study of anti-TGF? receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
|
|
Academic Article
|
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
|
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
|
Academic Article
|
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.
|
|
Academic Article
|
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
|
|
Academic Article
|
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
|
|
Academic Article
|
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.
|
|
Academic Article
|
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
|
|
Academic Article
|
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
|
|
Academic Article
|
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
|
|
Academic Article
|
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
|
|
Academic Article
|
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
|
|
Academic Article
|
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
|
|
Academic Article
|
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
|
|
Academic Article
|
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
|